Masimo Corporation Aktie News

IRVINE, Calif. , Nov. 18, 2025 /PRNewswire/ -- A team from Knobbe Martens led medical device pioneer Masimo (NASDAQ: MASI) to a victory over Apple in a dispute involving Masimo's patented heart monitoring technology.

DRC congratulates Knobbe Martens on a decisive jury verdict awarding its client Masimo more than $634 million in an Apple Watch patent infringement case.

Sold 45,000 shares in Masimo, reducing reported position by $7,569,900 Transaction represents a 4.0301% change in 13F reportable assets under management (AUM) Post-trade stake: 0 shares, $0 reported value The position was previously 4.0699% of the fund's AUM as of the prior quarter, marking a full exit this period

A federal jury in California ruled Friday that Apple must pay medical device maker Masimo $634 million for infringing a patent on blood oxygen monitoring technology.

A federal jury in California said on Friday that Apple owes medical-monitoring technology company Masimo $634 million for infringing a patent covering blood-oxygen reading technology.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today issued the following statement in response to the jury verdict announced in the U.S. District Court for the Central District of California, which confirmed the validity of Masimo Patent No. 10,433,776, found Apple infringed this patent, and awarded Masimo $634 million in damages: “We are pleased by this outcome, and appreciate the tim...

Masimo Corporation ( MASI ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Eli Kammerman - Vice President of Business Development & Investor Relations Catherine Szyman - CEO & Director Micah Young - Chief Financial Officer Conference Call Participants Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Jason Bednar - Piper Sandler & Co., Researc...

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371.5 million, representing 8.2% growth on a reported basis; Non-GAAP revenue of $371.2 million, representing 7.6% growth on a constant currency basis(2); GAAP net incom...